"instanceType","id","versionIdentifier","uuid:ID","rationale"
"StudyVersion","StudyVersion_1","2","d1899b35-efd2-4daf-b2d3-3ed84e3f3d03","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
